Altimmune CEO Acquires 20,000 Shares Before Phase 3 Pemvidutide Trial
Altimmune CEO Jerry Durso purchased 20,000 shares at $3.54, raising his total holdings to 32,500 shares as a show of confidence. The company is preparing a pivotal Phase 3 trial of pemvidutide for metabolic dysfunction-associated steatohepatitis using balanced one-to-one glucagon and GLP-1 agonism.
1. Insider Share Purchase
On March 6, 2026, CEO Jerry Durso acquired 20,000 shares of Altimmune common stock at $3.54 per share, increasing his total ownership to 32,500 shares. This transaction underscores executive confidence in the company’s strategic direction, particularly in its liver disease pipeline.
2. Phase 3 Trial Plans
Altimmune is gearing up for a pivotal Phase 3 program evaluating pemvidutide in metabolic dysfunction-associated steatohepatitis, addressing a high unmet medical need in liver disease. The trial design will assess efficacy on liver fat reduction, inflammation, and fibrosis in affected patients.
3. Mechanism of Action
Pemvidutide employs a proprietary balanced one-to-one agonism of glucagon and GLP-1, aiming to reduce liver fat and inflammation via glucagon activity while promoting weight loss and appetite suppression through GLP-1. This dual mechanism could differentiate the therapy in the NASH treatment landscape.
4. Stock Performance and Valuation
Altimmune’s shares are trading around $3.54, with a 52-week range of $2.90 to $7.73 and a market capitalization near $312.4 million. The stock’s recent 0.99% uptick reflects investor interest following the insider purchase and upcoming clinical milestones.